328 related articles for article (PubMed ID: 30078497)
21. Chronic Neutrophilic Leukemia: Current and Future Perspectives.
Venugopal S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):129-134. PubMed ID: 30581159
[TBL] [Abstract][Full Text] [Related]
22. Atypical chronic myeloid leukemia: a rare entity with management challenges.
Dhakal P; Gundabolu K; Amador C; Rayamajhi S; Bhatt VR
Future Oncol; 2018 Jan; 14(2):177-185. PubMed ID: 29226717
[TBL] [Abstract][Full Text] [Related]
23. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.
Castellino A; Santambrogio E; Rapezzi D; Massaia M
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684141
[TBL] [Abstract][Full Text] [Related]
24. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
25. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
Sadigh S; Hasserjian RP; Hobbs G
Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
[TBL] [Abstract][Full Text] [Related]
26. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract][Full Text] [Related]
27. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
[No Abstract] [Full Text] [Related]
28. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
[TBL] [Abstract][Full Text] [Related]
30. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
[TBL] [Abstract][Full Text] [Related]
31. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
32.
Iaquinta G; Scalzulli E; Angeloni S; Carmosino I; Costa A; Ielo C; Passucci M; Masucci C; Martelli M; Grammatico P; Breccia M
Leuk Lymphoma; 2023 Oct; 64(10):1730-1732. PubMed ID: 37435984
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq.
Sheng G; Zhang J; Zeng Z; Pan J; Wang Q; Wen L; Xu Y; Wu D; Chen S
Cancer Genet; 2017 Oct; 216-217():16-19. PubMed ID: 29025591
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study.
Klein SK; Huls GA; Visser O; Kluin-Nelemans HC; Dinmohamed AG
Blood Adv; 2023 Dec; 7(24):7554-7563. PubMed ID: 37934881
[TBL] [Abstract][Full Text] [Related]
35. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
36.
Linder K; Iragavarapu C; Liu D
Biomark Res; 2017; 5():33. PubMed ID: 29225884
[TBL] [Abstract][Full Text] [Related]
37. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
[TBL] [Abstract][Full Text] [Related]
38. [Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia].
Gritsaev SV; Kostroma II; Zapreev IM; Shmidt AV; Tiranova SA; Balashova VA; Martynkevich IS; Chubukina ZV; Semenova NY; Chechetkin AV
Ter Arkh; 2016; 88(7):104-108. PubMed ID: 27459623
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathogenesis of
Fontana D; Gambacorti-Passerini C; Piazza R
Front Oncol; 2021; 11():756348. PubMed ID: 34858828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
